Nationwide Fund Advisors lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 48.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 173,157 shares of the pharmaceutical company’s stock after buying an additional 56,646 shares during the quarter. Nationwide Fund Advisors owned approximately 0.07% of Vertex Pharmaceuticals worth $26,327,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Strs Ohio raised its stake in Vertex Pharmaceuticals by 11.4% in the third quarter. Strs Ohio now owns 378,589 shares of the pharmaceutical company’s stock valued at $57,560,000 after purchasing an additional 38,724 shares in the last quarter. Sanders Morris Harris LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $1,117,000. APG Asset Management N.V. raised its stake in Vertex Pharmaceuticals by 12.9% in the third quarter. APG Asset Management N.V. now owns 78,068 shares of the pharmaceutical company’s stock valued at $11,869,000 after purchasing an additional 8,900 shares in the last quarter. Oakbrook Investments LLC raised its stake in Vertex Pharmaceuticals by 5.3% in the third quarter. Oakbrook Investments LLC now owns 20,775 shares of the pharmaceutical company’s stock valued at $3,159,000 after purchasing an additional 1,050 shares in the last quarter. Finally, Meeder Asset Management Inc. raised its stake in Vertex Pharmaceuticals by 7.2% in the third quarter. Meeder Asset Management Inc. now owns 12,508 shares of the pharmaceutical company’s stock valued at $1,902,000 after purchasing an additional 840 shares in the last quarter. 92.42% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on VRTX. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Robert W. Baird reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. HC Wainwright reaffirmed a “hold” rating and issued a $85.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $173.15.

In related news, EVP Stuart A. Arbuckle sold 6,290 shares of Vertex Pharmaceuticals stock in a transaction on Friday, October 27th. The shares were sold at an average price of $143.97, for a total value of $905,571.30. Following the sale, the executive vice president now owns 116,952 shares in the company, valued at $16,837,579.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 220,315 shares of company stock worth $32,107,270. 1.80% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $146.55 on Friday. The stock has a market cap of $37,062.93, a P/E ratio of 244.25, a PEG ratio of 3.72 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $71.46 and a fifty-two week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share. research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Stake Raised by Nationwide Fund Advisors” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-stake-raised-by-nationwide-fund-advisors/1727103.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.